Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $25.67

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have been given an average recommendation of “Buy” by the eight research firms that are covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $25.67.

Several equities analysts have weighed in on ATXS shares. Oppenheimer raised their target price on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Citizens Jmp upgraded Astria Therapeutics to a “strong-buy” rating in a report on Friday, January 31st. JMP Securities began coverage on Astria Therapeutics in a report on Friday, January 31st. They set an “outperform” rating and a $26.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research report on Thursday, January 23rd.

Institutional Investors Weigh In On Astria Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ATXS. FMR LLC grew its position in shares of Astria Therapeutics by 29.2% in the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after purchasing an additional 1,767,714 shares during the last quarter. Vestal Point Capital LP grew its position in Astria Therapeutics by 23.1% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock worth $44,040,000 after buying an additional 750,000 shares in the last quarter. Redmile Group LLC acquired a new stake in Astria Therapeutics during the third quarter worth about $3,423,000. Cubist Systematic Strategies LLC acquired a new stake in Astria Therapeutics during the second quarter worth about $2,561,000. Finally, Charles Schwab Investment Management Inc. grew its position in Astria Therapeutics by 152.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company’s stock worth $3,460,000 after buying an additional 189,727 shares in the last quarter. 98.98% of the stock is owned by institutional investors and hedge funds.

Astria Therapeutics Price Performance

NASDAQ ATXS opened at $7.02 on Friday. Astria Therapeutics has a fifty-two week low of $6.64 and a fifty-two week high of $16.90. The stock’s 50-day moving average is $8.39 and its two-hundred day moving average is $10.17. The firm has a market cap of $396.14 million, a P/E ratio of -3.36 and a beta of 0.67.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.